ICON Public (NASDAQ:ICLR – Get Free Report) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $13.00-15.00 for the period, compared to the consensus estimate of $14.86. The company issued revenue guidance of $8.05-8.65 billion, compared to the consensus revenue estimate of $8.50 billion. ICON Public also updated its FY 2024 guidance to 13.900-14.100 EPS.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. cut their target price on shares of ICON Public from $375.00 to $280.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Leerink Partners reissued an “outperform” rating and issued a $255.00 price target (down previously from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. StockNews.com downgraded ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Barclays reduced their price target on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Finally, The Goldman Sachs Group dropped their price objective on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $287.00.
ICON Public Stock Performance
ICON Public (NASDAQ:ICLR – Get Free Report) last released its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). The business had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company’s revenue was down 1.2% compared to the same quarter last year. During the same period last year, the firm earned $3.10 EPS. On average, sell-side analysts predict that ICON Public will post 13.42 earnings per share for the current fiscal year.
ICON Public Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Articles
- Five stocks we like better than ICON Public
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Can Integrated Healthcare Stocks Succeed in Public Markets?
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- What Lucid’s Partnership With SoundHound Means for LCID Stock
- How to Use the MarketBeat Dividend Calculator
- Carnival: 4 Reasons to Set Sail in This Stock in 2025
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.